Central insulin‐like growth factor‐1 ( IGF ‐1) restores whole‐body insulin action in a model of age‐related insulin resistance and IGF ‐1 decline
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Low insulin-like growth factor-1 (IGF-1) signaling is associated with improved longevity, but is paradoxically linked with several age-related diseases in humans. Insulin-like growth factor-1 has proven to be particularly beneficial to the brain, where it confers protection against features of neuronal and cognitive decline. While aging is characterized by central insulin resistance in the face of hyperinsulinemia, the somatotropic axis markedly declines in older humans. Thus, we hypothesized that increasing IGF-1 in the brain may prove to be a novel therapeutic alternative to overcome central insulin resistance and restore whole-body insulin action in aging. Utilizing hyperinsulinemic-euglycemic clamps, we show that old insulin-resistant rats with age-related declines in IGF-1 level demonstrate markedly improved whole-body insulin action, when treated with central IGF-1, as compared to central vehicle or insulin (P < 0.05). Furthermore, central IGF-1, but not insulin, suppressed hepatic glucose production and increased glucose disposal rates in aging rats (P < 0.05). Taken together, IGF-1 action in the brain and periphery provides a 'balance' between its beneficial and detrimental actions. Therefore, we propose that strategies aimed at 'tipping the balance' of IGF-1 action centrally are the optimal approach to achieve healthy aging and longevity in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Géloën, A., Even, P. C., Cervera, P., & Le Bouc, Y. (2003) · Nature · doi:10.1038/nature01298 · Cited by 2,109 · cited 5×
“Moreover, low IGF-1 action is relevant to humans because of its link to less cancer risk (Renehan et al., 2004), an observation that spurred the development of IGF-1R antagonists as a clinical cancer treatment (Pollak, 2012).”
BackgroundInfluentialThorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
Hypothalamic insulin signaling is required for inhibition of glucose production
Obici, S., Zhang, B. B., Karkanias, G., & Rossetti, L. (2002) · Nature Medicine · doi:10.1038/nm1202-798 · Cited by 904 · cited 3×
“We performed hyperinsulinemic-euglycemic clamp studies with ICV infusion of aCSF, IGF-1, or insulin, as described (Obici et al., 2002; Muzumdar et al., 2006a).”
BackgroundMethodThe Critical Role of Metabolic Pathways in Aging
Barzilai, N., Huffman, D. M., Muzumdar, R. H., & Bartke, A. (2012) · Diabetes · doi:10.2337/db11-1300 · Cited by 803 · cited 3×
“Diminished growth hormone/insulin-like growth factor-1 (GH/IGF-1) signaling improves longevity across nature, including mice heterozygous for the IGF-1 receptor (IGF-1R) (Holzenberger et al., 2003; Barzilai et al., 2012).”
BackgroundSelf-citationFunctionally significant insulin-like growth factor I receptor mutations in centenarians
Suh, Y., Atzmon, G., Cho, M.-O., Hwang, D., Liu, B., Leahy, D. J., Barzilai, N., & Cohen, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705467105 · Cited by 703 · cited 2×
“Furthermore, our group has reported on a novel, functional mutation in the human IGF-1R gene (R407H) that is enriched in centenarians and results in attenuated IGF-1R signaling (Suh et al., 2008).”
BackgroundSelf-citationJuul, A., Scheike, T., Davidsen, M., Gyllenborg, J., & Jørgensen, T. (2002) · Circulation · doi:10.1161/01.cir.0000027563.44593.cc · Cited by 640
Sandhu, M. S., Heald, A. H., Gibson, J. M., Cruickshank, J. K., Dunger, D. B., & Wareham, N. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08655-5 · Cited by 470
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00005 · Cited by 370 · cited 3×
“However, beneficial outcomes could not be validated in subsequent trials (Liu et al., 2007), which, coupled with numerous side effects linked to chronic treatment, have precluded aging”
BackgroundInfluentialUncoupling lifespan and healthspan in Caenorhabditis elegans longevity mutants
Bansal, A., Zhu, L. J., Yen, K., & Tissenbaum, H. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412192112 · Cited by 367
Leng, S. X., Cappola, A. R., Andersen, R. E., Blackman, M. R., Koenig, K., Blair, M., & Walston, J. D. (2004) · Aging Clinical and Experimental Research · doi:10.1007/bf03324545 · Cited by 270 · cited 2×
“Paradoxically, low IGF-1 levels are associated with increased risk for numerous diseases of aging in humans, including cardiovascular disease (CVD) (Juul et al., 2002), type 2 diabetes (T2DM) (Sandhu et al., 2002), and frailty (Leng et al., 2004).”
Background
Cited by
Insulin-like growth factor-1 deficiency and metabolic syndrome
Aguirre, G. A., De Ita, J. R., de la Garza, R. G., & Castilla-Cortazar, I. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-015-0762-z · Cited by 295
Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice
Mao, K., Quipildor, G. F., Tabrizian, T., Novaj, A., Guan, F., Walters, R. O., Delahaye, F., Hubbard, G. B., Ikeno, Y., Ejima, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04805-5 · Cited by 167
Self-citationMilman, S., Huffman, D. M., & Barzilai, N. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.014 · Cited by 150
“, 2006) to regulate glucose homeostasis, though centrally acting IGF-1 proved more potent than insulin in regulating peripheral glucose fluxes in aging (Huffman et al., 2016).”
InfluentialSelf-citationHodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Self-citationCarter, C. S., Richardson, A., Huffman, D. M., & Austad, S. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz298 · Cited by 51
Self-citationOrganotypic cultures as aging associated disease models
Sanchez, M. M., Bagdasarian, I. A., Darch, W., & Morgan, J. T. (2022) · Aging · doi:10.18632/aging.204361 · Cited by 12
Metadata
- Authors
- Huffman, D. M., Farias Quipildor, G., Mao, K., Zhang, X., Wan, J., Apontes, P., Cohen, P., & Barzilai, N.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2015-11-04
- Volume
- 15
- Issue
- 1
- Pages
- 181-186
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2102207014
- Cited by
- 45
- References
- 12
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.